# Boston Immune Technologies & Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boston-immune-technologies-therapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.bostonimmunetech.com
- Total disclosed funding: $10M
- Latest round: Series A (Mar 17, 2021)
- Investors on record: 2

## About

Founded in 2011 and based in Virginia, US, Boston Immune Technologies & Therapeutics, Inc. operates as a developer of novel TNF (tumor necrosis factor) superfamily antagonist antibodies. The firm was co-founded by Russell LaMontagne and has raised series A funding at USD 10 million in March 2021.

Boston Immune Technologies & Therapeutics, Inc. develops tumor necrosis factor receptor superfamily antibodies including CD40 antagonists for inflammation and CD30 antagonists for oncology.

## Funding rounds

- Series A, Mar 17, 2021, $10M — Hatteras Venture Partners, BeiGene Ltd.

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- BeiGene Ltd. — Series A